{"id":"NCT00517933","sponsor":"Duke University","briefTitle":"Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis","officialTitle":"Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2009-05","completion":"2009-10","firstPosted":"2007-08-17","resultsPosted":"2013-08-23","lastUpdate":"2015-06-24"},"enrollment":180,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Fibrosis","Hypertension, Pulmonary"],"interventions":[{"type":"DRUG","name":"Sildenafil Citrate","otherNames":["Revatio"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sildenafil","type":"ACTIVE_COMPARATOR"},{"label":"Placebo / Sildanafil","type":"PLACEBO_COMPARATOR"}],"summary":"Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at improving breathing function, exercise capacity, and quality of life in people with advanced IPF.","primaryOutcome":{"measure":"Change in 6-minute Walk Distance From Enrollment to Week 12 (â‰¥ 20% Improvement)","timeFrame":"Measured at Week 12","effectByArm":[{"arm":"Sildenafil","deltaMin":9,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.39"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":35},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["26111071","25890798","20484178"],"seeAlso":["http://www.ipfnet.org"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":89},"commonTop":["Headache","Dyspnea","Diarrhoea","Cough","Oedema peripheral"]}}